Chemotherapy in the management of brain metastases: The emerging role of fotemustine for patients with melanoma and NSCLC

Expert Opinion on Drug Safety

Volumn 12, Issue 5, 2013, Pages 729-740

  Addeo, Raffaele ^a   Zappavigna, Silvia ^b   Luce, Amalia ^b   Facchini, Sergio ^b   Caraglia, Michele ^b  

^a S Giovanni di Dio Hospital   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Blood brain barrier; Brain metastasis; Fotemustine; Melanoma; Nitrosourea; Non small cell lung cancer

Indexed keywords

ALPHA INTERFERON; AMIFOSTINE; CISPLATIN; DACARBAZINE; FOTEMUSTINE; GEMCITABINE; INTERLEUKIN 2; IPILIMUMAB; NAVELBINE; PACLITAXEL; TEMOZOLOMIDE; VEMURAFENIB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRAIN INFECTION; BRAIN METASTASIS; BRAIN RADIATION; BRAIN TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHEMICAL STRUCTURE; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LEUKOPENIA; LIPOPHILICITY; LIVER TOXICITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; METASTATIC MELANOMA; MULTICENTER STUDY (TOPIC); NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; LUNG NEOPLASMS; MELANOMA; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS;

EID: 84882969783     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.789017     Document Type: Review

References (81)

1. Walker AE, Robins M, Weinfeld FD. Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology 1985;35(2):219-26
2. Johnson JD, Young B. Demographics of cerebral metastasis. Neurosurg Clin N Arn 1996;7:337-44
3. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322(8):494-500
4. Legha SS. Treatment of brain metastases from melanoma. J Clin Oncol 2005;23:3155-6
5. Kienast Y, Winkler F. Therapy and prophylaxis of brain metastases. Expert Rev Anticancer Ther 2010;10(11):1763-77
6. Posner JB. Management of central nervous system metastasis. Semin Oncol 1977;4:81-91
7. Addeo R, Cimmino G, Prete SD. Chemotherapy for brain metastasis and quality of life in handbook of disease burdens and quality of life measures. Springer 2010;162:2781-96
8. NCCN Central Nervous System Cancer Version 2. 2012. Available from: http://www.nccn.org/professionals/physician-gls/pdf/cns.pdf [Accessed 13 August 2012]
9. Chao JH, Phillips R, Nickson JJ. Roentgen ray therapy for cerebral metastases. Cancer 1954;7:682-9
10. Gaspar LE, Mehta MP, Patchell RA, et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. Neurooncology 2010;96(1):17-32
11. Taimur S, Edelman MJ. Treatment options for brain metastases in patients with non-small cell lung cancer. Curr Treat Options Oncol 4:89-95.2003
12. Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist 2007;12(7):884-98
13. Lassman AB, DeAngelis LM. Brain metastases. Neurol Clin N Am 2003;21:1-23
14. Gerstner ER, Fine RL. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 2007;25(16):2306-12
15. De Rossi A, Rossi L, Laudisi A, et al. Focus on fotemustine. J Exp Clin Cancer Res 2006;25(4):461-8
16. Silvani A, Gaviani P, Lamperti E, et al. Lecture: fotemustine in brain tumors. Neurol Sci 2011;32(Suppl 2):S255-7
17. Kyritsis AP, Levin VA. An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting. Cancer Chemother Pharmacol 2011;67(5):971-83 .
18. Meulemans A, Giroux B, Hannoun P, et al. Comparative diffusion study of two nitrosoureas: carmustine and fotemustine in normal rat brain, human and rat brain biopsies. Chemotherapy 1991;37(2):86-92
19. Hayes MT, Bartley J, Parsons PG, et al. Mechanism of action of fotemustine, a new chloroethylnitrosourea anticancer agent: evidence for the formation of two DNA-reactive intermediates contributing to cytotoxicity. Biochemistry 1997;36(35):10646-54
20. Passagne I, Evrard A, Winum JY, et al. Cytotoxicity, DNA damage, and apoptosis induced by new fotemustine analogs on human melanoma cells in relation to O6-methylguanine DNAmethyltransferase expression. J Pharmacol Exp Ther 2003;307(2):816-23
21. Lokiec F, Beerblock K, Deloffre P, et al. Study of the clinical pharmacokinetics of fotemustine in various tumor indications. Bull Cancer 1989;76(10):1063-9
22. Filippeschi S, Colombo T, Bassani D, et al. Antitumor activity of the novel nitrosourea S10036 in rodent tumors. Anticancer Res 1988;8(6):1351-4
23. Iliadis A, Launay-Iliadis MC, Lucas C, et al. Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: a French cancer centre multicentric study. Eur J Cancer 1996;32A(3):455-60
24. Ings RM, Gray AJ, Taylor AR, et al. Disposition, pharmacokinetics, and metabolism of 14C-fotemustine in cancer patients. Eur J Cancer 1990;26(7):838-42
25. Riviere A, Le Cesne A, Berille J, et al. Cisplatin-fotemustine combination in inoperable non-small cell lung cancer: preliminary report of a French multicentre phase II trial. Eur J Cancer 1994;30A(5):587-90
26. Rigal-huguet F, Gaspard MH, Attal M, et al. Clinical pharmacokinetics of fotemustine with assessment of passage across the blood-brain barrier. Bull Cancer 1990;21:775-91
27. Meulemans A, Giroux B, Hannoun P, et al. Permeability of two nitrosoureas, carmustine and fotemustine in rat cortex. Chemotherapy 1989;35(5):313-19
28. Fischel JL, Formento P, Etienne MC, et al. In vitro chemosensitivity testing of fotemustine (S 10036), a new antitumor nitrosourea. Cancer Chemother Pharmacol 1990;25(5):337-41
29. Khayat D, Lokiec F, Bizzari JP, et al. Phase I clinical study of the new amino acid linked nitrosourea, S 10036, administered on a weekly schedule. Cancer Res 1987;47(24 Pt 1):6782-5
30. Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990;66:1873-8
31. Jacquillat C, Khayat D, Banzet P, et al. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemother Pharmacol 1990; 25(4):263-6
32. Merimsky O, Inbar M, Gerard B, Chaitchik S. Fotemustine - an advance in the treatment of metastatic malignant melanoma. Melanoma Res 1992;2(5-6):401-6
33. Chang J, Atkinson H, A'Hern R, et al. A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma. Eur J Cancer 1994;30A(14):2093-5
34. Falkson CI, Falkson G, Falkson HC. Phase II trial of fotemustine in patients with metastatic malignant melanoma. Invest New Drugs 1994;12(3):251-4
35. Kleeberg UR, Engel E, Israels P, et al. Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG). Melanoma Res 1995;5(3):195-200
36. Calabresi F, Aapro M, Becquart D, et al. Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma. Ann Oncol 1991;2:377-8
37. Schallreuter KU, Wenzel E, Brassow FW, et al. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine. Cancer Chemother Pharmacol 1991;29:85-7
38. Ristic-Fira A, Koric?nac L, Ẑakula J, et al. Proton inactivation of melanoma cells enhanced by fotemustine. Radiat Prot Dosimetry 2011;143(2-4):503-7
39. Brocker EB, Bohndorf W, Kampgen E, et al. Fotemustine given simultaneously with total brain irradiation in multiple brain metastases of malignant melanoma: report on a pilot study. Melanoma Res 1996;6(5):399-401
40. Ridolfi L, Fiorentini G, Guida M, et al. Italian Melanoma Intergroup. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients. Melanoma Res 2009;19(2):100-5
41. Avril MF, Bonneterre J, Cupissol D, et al. Fotemustine plus dacarbazine for malignant melanoma. Eur J Cancer 1992;28A(11):1807-11
42. Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004;22:1118-25
43. Mornex F, Thomas L, Mohr P, et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res 2003;13(1):97-103
44. Wu PF, Kuo KT, Kuo LT, et al. O(6)- Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers. Lung Cancer 2010;68(3):484-90
45. Le Chevalier T, Zabbe C, Gouva S, et al. Phase II multicentre study of the nitrosourea fotemustine in inoperable squamous cell lung carcinoma. Eur J Cancer Clin Oncol 1989;25(11):1651-2
46. Le Cesne A, Chabot G, Berille J, et al. Phase I-II and pharmacokinetic study of a new fotemustine schedule in advanced non-small cell lung cancer. Lung Cancer 1995;13(1):69-78
47. Rudd R, Allen R, Berille J, et al. Phase II study of fotemustine in untreated inoperable non-small-cell lung cancer. Cancer Chemother Pharmacol 1994;34(5):444-6
48. Pujol JL, Monnier A, Berille J, et al. Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer. Br J Cancer 1994;69(6):1136-40
49. Cotto C, Berille J, Souquet PJ, et al. A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer. Eur J Cancer 1996;32A(1):69-71
50. Galetta D, Gebbia V, Silvestris N, et al. Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: a multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603). Lung Cancer 2011;72(1):59-63
51. Khayat D, Giroux B, Berille J, et al. Fotemustine in the treatment of brain primary tumors and metastases. Cancer Invest 1994;12(4):414-20
52. Mohr P, Makki A, Breitbart E, Schadendorf D. Combined treatment of stage IV melanoma patients with amifostine and fotemustine - a pilot study. Melanoma Res 1998;8:166-9
53. Raymond E, Haon C, Boaziz C, Coste M. Logistic regression model of fotemustine toxicity combining independent phase II studies. Cancer 1996;78:1980-7
54. Stevens MFG, Hickman JA, Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8- carbomoyl-3-methyl-imidazo[5,1-d]- 1,2,3,5-tetrazin- 4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative dacarbazine. Cancer Res 1987;47:5846-52
55. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Can Res 2000;6(7):2585-97
56. Trinh VA, Patel SP, Hwu WJ. The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf 2009;8(4):493-9
57. Quirt I, Verma S, Petrella T, et al. Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist 2007;12(9):1114-23
58. Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004;22(11):2101-7
59. Tas F, Camlica H, Topuz E. Temozolomide in combination with fotemustine in patients with metastatic melanoma. Cancer Chemother Pharmacol 2008;62(2):293-8
60. Soffietti R, Trevisan E, Ruda R. Targeted therapy in brain metastasis. Curr Opin Oncol 2012;24(6):679-86
61. Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7(2):95-106
62. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012;13(5):459-65
63. Kleisbauer JP, Guerin JC, Arnaud A, et al. Chemotherapy with high-dose cisplatin in brain metastasis of lung cancers. Bull Cancer 1990;77:661-5; French
64. Cortes J, Rodriguez J, Aramendia JM, et al. Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology 2003;64:28-35
65. Christodoulou C, Bafaloukos D, Kosmidis P, et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 2001;12:249-54
66. Dziadziuszko R, Ardizzoni A, Postmus PE, et al. Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases: a phase II study of the EORTC Lung Cancer Group (08965). Eur J Cancer 2003;39:1271-6
67. Giorgio CG, Giuffrida D, Pappalardo A, et al. Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study. Lung Cancer 2005;50:247-54
68. Cortot AB, Geriniere L, Robinet G, et al. Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study. Ann Oncol 2006;17(9):1412-17
69. Addeo R, Caraglia M. Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera? Expert Opin Investig Drugs 2011;20(7):881-95
70. Antonadou D, Paraskevaidis M, Sarris M, et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002;20:3644-50
71. Verger E, Gil M, Yaya R, et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 2005;61:185-91
72. Kouvaris JR, Miliadou A, Kouloulias VE, et al. Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors. Onkologie 2007;30(7):361-6
73. Addeo R, Caraglia M, Faiola V, et al. Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life. BMC Cancer 2007;7:18
74. Chua D, Krzakowski M, Chouaid C, et al. Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study. Clin Lung Cancer 2010;11(3):176-81
75. Addeo R, De Rosa C, Faiola V, et al. Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for non small cell lung cancer and breast cancer patients with brain metastases. Cancer 2008;113(9):2524-31
76. Shimato S, Mitsudomi T, Kosaka T, et al. EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. Neurooncology 2006;8:137-44
77. Ceresoli GL, Cappuzzo F, Gregorc V, et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 2004;15:1042-7
78. De Braganca KC, Janjigian YY, Azzoli CG, et al. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neurooncol 2010;100(3):443-7
79. Di Giacomo AM, Ascierto PA, Pilla L, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 2012;13(9):879-86
80. Del Vecchio M, Mortarini R, Canova S, et al. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors. Clin Cancer Res 2010;16(23):5862-72
81. Addeo R, Caraglia M, De Santi MS, et al. A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. J Neurooncol 2011;102(3):417-24